Clinical Trials

Clinical Trial Detail

Return to search results.

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate Cancer

Complete title: Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy

Research Study Number       6932
Principal Investigator       Robert Montgomery, MD
Phase       NA

Look up trial at NIH

Research Study Description

This research trial collects and studies tissue and blood samples from patients with prostate cancer that is locally recurrent or has spread to other parts of the body. Studying samples of blood and tissue samples from patients with prostate cancer in the laboratory may help doctors learn more about new biomarkers, potential drug targets, and resistance developing in response to treatment. It may also help doctors find better ways to treat prostate cancer.

Eligibility Criteria (must meet the following to participate in this study)

Ages Eligible for Study: 18 Years and older

Genders Eligible for Study: Male

Sampling Method: Non-Probability Sample

Study Population:

Patients with prostate cancer treated in genitourinary oncology practices at University of Washington Medical Center, Seattle Cancer care Alliance and Harborview Medical Center

- Ability to adequately understand and give informed consent

- Local (prostate or prostate bed) recurrent castration resistant prostate cancer (CRPC) or metastatic disease to soft tissue or bone at sites accessible to biopsy with minimal risk of complications

- Platelet count > 50,000

- White blood cell (WBC) > 1,500

- Hemoglobin (Hgb) > 8.0

- International normalized ratio (INR) < 1.5

- Partial thromboplastin time (PTT) < 45

- No history of excessive unexplained bleeding from previous surgery

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

- Patients unable to stop chronic anticoagulation with warfarin or Lovenox for less than 3 days

- Serious or uncontrolled infection

- Treatment with a vascular endothelial growth factor (VEGF) inhibitor (such as Avastin) within the past 28 days

Other exclusion criteria may apply.

Research Study Number       6932
Contact       Robert Montgomery, MD
Telephone       206/598-0860

Genitourinary Cancer; Prostate Cancer; Solid Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials